PARP Inhibitor Market, by Drug Type (Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), and Talazoparib (Talzenna)), by Application (Ovarian Cancer, Breast Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis 2022-2028

The PARP Inhibitor Cancer Therapy Market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). Key players’ focus on research and development to develop new products is anticipated to drive the market. For example, in May 2020, the Food and Drug Administration approved the poly ADP-ribose polymerase (PARP) inhibitor monotherapy niraparib as first-line treatment for ovarian cancer. In November 2020, AstraZeneca and MSD’s Lynparza (olaparib) received European Union (EU) approval for metastatic castration-resistant prostate cancer (mCRPC) patients with breast cancer.

Furthermore, the increasing prevalence of cancer globally is likely to drive the global market for PARP inhibitors. For example, according to the US Surveillance, Epidemiology, and End Results (SEER) Program, in 2016 there were approximately 229,875 women living with ovarian cancer diagnoses.

 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Market Segmentation

By Indication

• Breast Cancer
• Ovarian cancer
• Prostate cancer
• Pancreatic cancer
• Others

By Drug Type

• Olaparib
• Niraparib
• Rucaparib
• Talazoparib
• Veliparib
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Key Players

Major players operating in the global PARP inhibitor market include AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline Plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol Myers Squibb, Merck KGaA, Genentech, Inc., Artios Pharma, Repare Therapeutics Inc., Sierra Oncology, Inc., KaryopharmTherapeutics Inc., Ono Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.

 Geographic Coverage

• North America Market Size and/or Volume
• Latin America Market Size and/or Volume
• Europe Market Size and/or Volume
• Asia-Pacific Market Size and/or Volume
• Rest of the world Market Size and/or Volume 

Recent Developments

• Market Overview and growth analysis
• Import and Export Overview
• Volume Analysis
• Current Market Trends and Future Outlook
• Market Opportunistic and Attractive Investment Segment